NASDAQ:BGLC BioNexus Gene Lab (BGLC) Stock Price, News & Analysis $1.34 +0.12 (+9.84%) As of 11:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About BioNexus Gene Lab Stock (NASDAQ:BGLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNexus Gene Lab alerts:Sign Up Key Stats Today's Range$1.28▼$1.4350-Day Range$1.22▼$1.6552-Week Range$1.07▼$5.89Volume24,216 shsAverage Volume43,634 shsMarket Capitalization$3.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation. The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets. BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market. The company was established in 2017 and has pursued a business model that combines biotechnology and diagnostic development with chemical distribution.AI Generated. May Contain Errors. Read More BioNexus Gene Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreBGLC MarketRank™: BioNexus Gene Lab scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioNexus Gene Lab has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNexus Gene Lab has only been the subject of 1 research reports in the past 90 days.Read more about BioNexus Gene Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNexus Gene Lab is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNexus Gene Lab is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNexus Gene Lab has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.44% of the float of BioNexus Gene Lab has been sold short.Short Interest Ratio / Days to CoverBioNexus Gene Lab has a short interest ratio ("days to cover") of 3.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNexus Gene Lab has recently increased by 74.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNexus Gene Lab does not currently pay a dividend.Dividend GrowthBioNexus Gene Lab does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.70 News SentimentBioNexus Gene Lab has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioNexus Gene Lab this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.Percentage Held by Insiders0.05% of the stock of BioNexus Gene Lab is held by insiders.Percentage Held by Institutions18.85% of the stock of BioNexus Gene Lab is held by institutions.Read more about BioNexus Gene Lab's insider trading history. Receive BGLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BGLC Stock News HeadlinesBioNexus Gene Lab Corp. (NASDAQ:BGLC) Shares Shorted: Short Interest Up 74.0% in SeptemberSeptember 30 at 3:01 AM | americanbankingnews.comBioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working VisitJuly 28, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 1 at 1:00 AM | Banyan Hill Publishing (Ad)BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-DevelopmentMay 29, 2026 | globenewswire.comBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard ...March 11, 2026 | markets.businessinsider.comBioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion DiagnosticsMarch 11, 2026 | quiverquant.comQBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD PlatformMarch 11, 2026 | globenewswire.comBioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as ChairmanFebruary 23, 2026 | globenewswire.comSee More Headlines BGLC Stock Analysis - Frequently Asked Questions How have BGLC shares performed this year? BioNexus Gene Lab's stock was trading at $4.1150 at the start of the year. Since then, BGLC stock has decreased by 70.4% and is now trading at $1.22. How were BioNexus Gene Lab's earnings last quarter? BioNexus Gene Lab Corp. (NASDAQ:BGLC) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.12) EPS for the quarter. The firm earned $0.08 million during the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative trailing twelve-month return on equity of 32.92%. When did BioNexus Gene Lab's stock split? BioNexus Gene Lab shares reverse split on the morning of Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did BioNexus Gene Lab IPO? BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering (IPO) on Thursday, July 20th 2023. The company issued 1,300,000 shares at $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO. How do I buy shares of BioNexus Gene Lab? Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNexus Gene Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/14/2026Today10/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BGLC's financial health is in the Red zone, according to TradeSmith. BGLC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:BGLC CIK1737523 Webwww.bionexusgenelab.com Phone60-1-2212-6512FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.98 million Net Margins-82.38% Pretax Margin-82.38% Return on Equity-32.92% Return on Assets-29.75% Debt Debt-to-Equity Ratio0.01 Current Ratio6.08 Quick Ratio5.28 Sales & Book Value Annual Sales$7.43 million Price / Sales0.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.38Miscellaneous Outstanding Shares2,930,000Free Float2,932,000Market Cap$3.93 million OptionableNot Optionable Beta4.19 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BGLC) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BGLC Stock Alerts